Silence Therapeutics Raises Approximately $175M in Upsized Public Offering to Accelerate siRNA Pipeline

Silence Therapeutics has priced an upsized underwritten public offering expected to generate about $175 million in gross proceeds, a move designed to fund late-stage development of its short interfering RNA (siRNA) therapies.

Offering Structure and Key Terms

Size, Pricing, and Proceeds

  • Silence is selling 12,962,963 American Depositary Shares (ADSs) at $13.50 per ADS.
  • Each ADS represents three ordinary shares of £0.05 in Silence Therapeutics plc.
  • Expected gross proceeds are approximately $175 million before underwriting discounts, commissions, and other offering expenses.
  • The figure excludes any additional funds from the underwriters’ option to buy more ADSs.

Underwriters’ Option and Closing Timeline

  • The underwriters have a 30-day option to purchase up to 1,944,444 additional ADSs at the same $13.50 price, less discounts and commissions.
  • The deal is expected to close on or about August 13, 2026, subject to customary closing conditions.
  • This “upsized” structure suggests strong investor demand relative to the company’s initial plans.

Why Silence Therapeutics Is Raising Capital Now

Funding Late-Stage siRNA Programs

Silence Therapeutics is a clinical-stage biotechnology company focused on developing precision siRNA medicines that silence disease-causing genes, particularly in liver-related, cardiometabolic, and blood disorders. The fresh capital comes as several key programs approach pivotal readouts:

  • Divesiran (TMPRSS6 siRNA) for polycythemia vera (PV):
    • Phase 2 SANRECO trial enrollment and dosing were completed in June 2026.
    • Top-line results are expected around mid-August 2026, shortly after this financing.
    • Phase 1 data showed durable hematocrit control with infrequent, fixed dosing, potentially reducing reliance on phlebotomies.
  • SLN312 (ANGPTL3 siRNA) for dyslipidemia, in collaboration with AstraZeneca:
    • Phase 1 data demonstrated favorable safety and clear, dose-dependent reductions in ANGPTL3 protein and atherogenic lipoproteins (LDL-C, Apo-B, non-HDL-C).
    • This positions Silence competitively in the crowded dyslipidemia space.
  • Zerlasiran and other cardiometabolic assets:
    • Zerlasiran (Lp(a)-targeting) is described as Phase III–ready, with partnership discussions ongoing pending external trial data.
    • Additional preclinical programs (e.g., SLN365 for lipids, SLN098 for obesity) are advancing toward IND submissions in 2027.

Strengthening the Balance Sheet Ahead of Catalysts

As of June 30, 2026, Silence reported $72.05 million in cash and cash equivalents, with no contract liabilities. Given the capital intensity of late-stage trials and potential global registration studies, the new $175 million gross proceeds materially extend the company’s runway:

  • Supports completion and follow-up of Phase 2/3 studies.
  • Funds potential expansion into additional indications (e.g., myelodysplastic syndromes, obesity).
  • Provides flexibility for partnerships, business development, or in-licensing opportunities.

Company Background and siRNA Technology

What Silence Therapeutics Does

Silence Therapeutics develops novel siRNA therapies designed to durably and reversibly silence specific genes involved in disease. The company leverages:

  • Proprietary siRNA chemistry and chemical modifications.
  • Linker and GalNAc ligand technologies for targeted liver delivery.
  • A global R&D footprint with hubs in London, Berlin, and New Jersey.

This “toolbox” approach allows Silence to optimize potency, durability, and safety across its pipeline in rare blood cancers and cardiometabolic diseases.

Strategic Focus and Competitive Positioning

Silence is prioritizing first-in-class or best-in-class positions in high-impact areas:

  • Polycythemia vera: Divesiran aims to be a first-line siRNA option with infrequent dosing and durable hematocrit control.
  • Dyslipidemia: SLN312 and zerlasiran target key lipid pathways (ANGPTL3, Lp(a)) with potential to complement or improve on existing therapies.
  • Obesity and metabolic disease: Early programs like SLN098 target visceral fat reduction while preserving lean mass, aligning with the booming metabolic therapeutics market.

The company’s collaboration with AstraZeneca on SLN312 underscores external validation of its platform and approach.

Market Reaction and Investor Considerations

Dilution vs. De-Risking Trade-Off

Equity offerings like this typically lead to share dilution, which can pressure the stock in the short term. However, investors often weigh:

  • Dilution: More shares outstanding can reduce per-share value if not offset by growth.
  • De-risking: Adequate funding reduces the risk of down-round financings, partnership distress, or program delays near critical data releases.

With multiple catalysts due in late 2026 and 2027, the market may view this capital raise as a strategic move to capture upside from positive trial outcomes.

Context From Recent Financials and Pipeline Progress

Silence’s Q2 2026 update highlighted:

  • Narrowing quarterly losses and disciplined financial management.
  • Zero reported revenue in Q2 2026 versus $224,000 in Q2 2025, reflecting its pre-commercial, clinical-stage status.
  • Strong clinical momentum in divesiran and SLN312, plus advancing preclinical assets.

The new capital complements up to $300 million in previously contemplated equity capacity (including at-the-market ADSs) to fund RNAi drug development.

What This Means for Patients and the siRNA Field

Potential Clinical Impact

If late-stage trials succeed, Silence’s siRNA therapies could:

  • Reduce or eliminate the need for frequent phlebotomies in PV patients.
  • Offer new options for patients with elevated Lp(a) or refractory dyslipidemia.
  • Contribute to next-generation metabolic treatments that target root genetic drivers rather than just symptoms.

Broader Implications for RNA Therapeutics

Silence’s progress adds to the growing evidence that siRNA can deliver:

  • Long-lasting gene silencing with infrequent dosing.
  • Favorable safety profiles when properly engineered and delivered.
  • Scalable platforms applicable across multiple diseases.

Successful outcomes could attract further investment and partnerships into the siRNA space, benefiting the broader RNA therapeutics ecosystem.

Frequently Asked Questions (FAQ)

How much money is Silence Therapeutics raising?

Silence expects gross proceeds of approximately $175 million from the offering, before underwriting discounts, commissions, and other expenses.

At what price are the ADSs being sold?

The ADSs are priced at $13.50 each, with 12,962,963 ADSs in the base offering.

Can the underwriters sell more shares?

Yes. The underwriters have a 30-day option to buy up to 1,944,444 additional ADSs at the same $13.50 price, less discounts and commissions.

When is the offering expected to close?

The transaction is expected to close on or about August 13, 2026, subject to customary closing conditions.

What will Silence use the proceeds for?

While not itemized in the announcement, the timing aligns with funding late-stage trials (including divesiran Phase 2/3), advancing dyslipidemia and Lp(a) programs, and supporting preclinical assets toward IND filings.

Does this offering affect existing shareholders?

Equity offerings typically increase the total number of shares, which can dilute existing ownership percentages. However, they also strengthen the balance sheet and reduce financing risk around key clinical milestones.

Is Silence Therapeutics profitable?

No. As a clinical-stage biotech, Silence reported no revenue in Q2 2026 and continues to invest heavily in R&D, with losses narrowing but still present.

Where is Silence Therapeutics based?

Silence operates globally with key hubs in London, Berlin, and New Jersey, focusing on liver-targeted siRNA therapies for cardiometabolic and blood disorders.

References

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research or consult a qualified financial advisor before making investment decisions.